IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications

Expert Rev Anticancer Ther. 2012 May;12(5):543-6. doi: 10.1586/era.12.32.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Bile Duct Neoplasms / drug therapy*
  • Bile Duct Neoplasms / enzymology
  • Bile Duct Neoplasms / genetics*
  • Cholangiocarcinoma / drug therapy*
  • Cholangiocarcinoma / enzymology
  • Cholangiocarcinoma / genetics*
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Isocitrate Dehydrogenase / antagonists & inhibitors
  • Isocitrate Dehydrogenase / genetics*
  • Isocitrate Dehydrogenase / metabolism
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Molecular Targeted Therapy
  • Mutation*

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Isoenzymes
  • Isocitrate Dehydrogenase